Some effects of the secondary hyperparathyreoisis in patients with chronic kidney disease
Abstract
A high incidence of secondary hyperparathyreosis (HPT) was found during examination of 106 patients with the 3-5 stage of chronic kidney disease (CKD). It was revealed in 22 (62,8%) patients with the 3 stage of CKD, in 25 (83,3%) patients with the 4 stage of CKD and in 39 (95,1%) patients with the 5 stage of CKD. The effects of HPT on hemopoiesis, lipid and protein exchange and also its role in the development of systemic inflammation and arterial hypertension peculiar to kidney insufficiency have been revealed. A correlation of parathyreoid hormone level and red blood readings, C-reactive protein, blood albumin in patients with the predialysis stage of CKD (3-4 stages of CKD) has been found. The necessity of diagnosing hyperparathyreosis in the early stages of CKD and timely treatment of this kind of kidney disfunction has been proved.
About the Authors
N. Y. Kuzina
Иркутский государственный медицинский университет, г. Иркутск
Russian Federation
Russian Federation
G. M. Orlova
Иркутский государственный медицинский университет, г. Иркутск
Russian Federation
Russian Federation
References
1. Ванер К. Метаболизм липидов при заболеваниях почек и почечной недостаточности. Сборник материалов международной нефрологической конференции «Современные аспекты заместительной терапии при почечной недостаточности». М.: 1998: 17-25.
2. Волгина Г.В. Паратиреоидный гормон - универсальный уремический токсин Нефрология и диализ 2000; 2; 1: 32-38.
3. Волгина Г.В. Вторичный гиперпаратиреоз при хронической почечной недостаточности. Лечение активными метаболитами витамина D. Нефрология и диализ 2004; 6; 2: 116.
4. Неопалитанский В.Ю., Шило В.Ю. Александров Ю.К. и соавт. Анемия при вторичном гиперпаратиреозе. Анемия 2005; 4: 25-29.
5. Jespersen B., Fogo-Andersen N., Brock A. Parathyroid hormone in blood pressure and volum homeostasis in healthy subjects, hyperparathyroidism, liver cirrhosis and glomerulonephritis. A possible interaction with angiotention 11 and atrial natriuretic peptide. Scand J Clin Lab Invest 1994; 54: 531-541.
6. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation Classification Stratification. Am J Kidney Dis 2002; 39 S: 1-266.
7. Levin A., Thompson C.R., Ethier J., Carlisle E.J., Tobe S., Mendelssohn D., Burgess E., Jindal K., Barrett B., Singer J., Djurdjev O. Left ventricular mass index increase in early renal disease Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
8. London C.M., Drueke T.B. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-1695.
9. Marcer R., Teruel J.L., de la Cal M.A., Gomes C. The impact of malnutrition in morbidity and mortality in stalle haemodialysis patients. Nephrol Dial Transplant 1997; 12: 2324-2331.
10. Pillai S., Birlke DD., Su M.J. et al. 1,25-Dihydroxyvitamin D3 upregulates the phosphatidyl-inositol signalling pathway in human keratinocytes by increasing phospholipase C level. J Clin Invest 1995; 96: 602-607.
11. Schluter K D., Piper H M. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol 1992; 263: 1739-1746.
Review
For citations:
Kuzina N.Y., Orlova G.M. Some effects of the secondary hyperparathyreoisis in patients with chronic kidney disease. Nephrology and Dialysis. 2008;10(2):140-143. (In Russ.)
Views:
6
Email this article 